DE69526934D1 - Medikamente zur behandlung von restenosis, enthaltend stickstoff freisetzende polymere - Google Patents

Medikamente zur behandlung von restenosis, enthaltend stickstoff freisetzende polymere

Info

Publication number
DE69526934D1
DE69526934D1 DE69526934T DE69526934T DE69526934D1 DE 69526934 D1 DE69526934 D1 DE 69526934D1 DE 69526934 T DE69526934 T DE 69526934T DE 69526934 T DE69526934 T DE 69526934T DE 69526934 D1 DE69526934 D1 DE 69526934D1
Authority
DE
Germany
Prior art keywords
nitric oxide
releasing
delivery means
medicines
restenosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69526934T
Other languages
English (en)
Other versions
DE69526934T2 (de
Inventor
K Keefer
C Hutsell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Comedicus Inc
Original Assignee
US Department of Health and Human Services
Comedicus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, Comedicus Inc filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69526934D1 publication Critical patent/DE69526934D1/de
Publication of DE69526934T2 publication Critical patent/DE69526934T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08FMACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00Chemical modification by after-treatment
    • C08F8/30Introducing nitrogen atoms or nitrogen-containing groups
    • C08F8/32Introducing nitrogen atoms or nitrogen-containing groups by reaction with amines
DE69526934T 1994-03-17 1995-03-09 Medikamente zur behandlung von restenosis, enthaltend stickstoff freisetzende polymere Expired - Fee Related DE69526934T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/214,372 US5650447A (en) 1992-08-24 1994-03-17 Nitric oxide-releasing polymers to treat restenosis and related disorders
PCT/US1995/003040 WO1995024908A1 (en) 1994-03-17 1995-03-09 Use of nitric oxide-releasing polymers to treat restenosis and related disorders

Publications (2)

Publication Number Publication Date
DE69526934D1 true DE69526934D1 (de) 2002-07-11
DE69526934T2 DE69526934T2 (de) 2003-01-02

Family

ID=22798839

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69526934T Expired - Fee Related DE69526934T2 (de) 1994-03-17 1995-03-09 Medikamente zur behandlung von restenosis, enthaltend stickstoff freisetzende polymere

Country Status (11)

Country Link
US (1) US5650447A (de)
EP (1) EP0752866B1 (de)
JP (1) JPH10502905A (de)
AT (1) ATE218352T1 (de)
AU (1) AU698525B2 (de)
CA (1) CA2185457C (de)
DE (1) DE69526934T2 (de)
DK (1) DK0752866T3 (de)
ES (1) ES2177637T3 (de)
PT (1) PT752866E (de)
WO (1) WO1995024908A1 (de)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5632981A (en) * 1992-08-24 1997-05-27 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
US6255277B1 (en) 1993-09-17 2001-07-03 Brigham And Women's Hospital Localized use of nitric oxide-adducts to prevent internal tissue damage
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
GB9423868D0 (en) * 1994-11-25 1995-01-11 Wellcome Found Compounds for use in medicine
ES2244966T3 (es) * 1994-12-12 2005-12-16 Omeros Corporation Solucion de irrigacion y su utilizacion para inhibir perioperatoriamente el dolor, la inflamacion y el espasmo en una herida.
US6063407A (en) * 1995-02-16 2000-05-16 The General Hospital Corporation Treatment of vascular thrombosis and restenosis with inhaled nitric oxide
US20050152950A1 (en) * 1995-11-13 2005-07-14 Saffran Bruce N. Method and apparatus for macromolecular delivery using a coated membrane
US5770645A (en) * 1996-08-02 1998-06-23 Duke University Medical Center Polymers for delivering nitric oxide in vivo
US6232434B1 (en) 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
AU3986097A (en) * 1996-08-27 1998-03-19 University Of Akron, The Lipophilic polyamine esters for the site specific delivery of nitric oxide in pharmaceutical use
US6372796B1 (en) * 1996-11-13 2002-04-16 Cold Spring Harbor Laboratory Therapeutic uses for nitric oxide inhibitors
US5994444A (en) * 1997-10-16 1999-11-30 Medtronic, Inc. Polymeric material that releases nitric oxide
US6221425B1 (en) 1998-01-30 2001-04-24 Advanced Cardiovascular Systems, Inc. Lubricious hydrophilic coating for an intracorporeal medical device
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US5962520A (en) * 1998-04-02 1999-10-05 The University Of Akron Hydrolytically unstable, biocompatible polymer
US6207855B1 (en) 1998-06-23 2001-03-27 Duke University Medical Center Stable no-delivering compounds
US20040043068A1 (en) * 1998-09-29 2004-03-04 Eugene Tedeschi Uses for medical devices having a lubricious, nitric oxide-releasing coating
US6645167B1 (en) * 1999-05-21 2003-11-11 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an embolizing composition
WO2000071064A1 (en) * 1999-05-21 2000-11-30 Micro Therapeutics, Inc. Methods for delivering in vivo uniform dispersed embolic compositions of high viscosity
US7018365B2 (en) 1999-05-21 2006-03-28 Micro Therapeutics, Inc. Threaded syringe with quick stop
WO2001010344A1 (en) * 1999-08-04 2001-02-15 C.R. Bard, Inc. Nitric oxide releasing medical devices
US6569082B1 (en) 1999-08-10 2003-05-27 Origin Medsystems, Inc. Apparatus and methods for cardiac restraint
US7597698B2 (en) * 1999-08-10 2009-10-06 Maquet Cardiovascular Llc Apparatus and method for endoscopic encirclement of pulmonary veins for epicardial ablation
US7288096B2 (en) 2003-01-17 2007-10-30 Origin Medsystems, Inc. Apparatus for placement of cardiac defibrillator and pacer
US20030187461A1 (en) * 1999-08-10 2003-10-02 Chin Albert K. Releasable guide and method for endoscopic cardiac lead placement
US20040102804A1 (en) * 1999-08-10 2004-05-27 Chin Albert K. Apparatus and methods for endoscopic surgical procedures
US7526342B2 (en) * 1999-08-10 2009-04-28 Maquet Cardiovascular Llc Apparatus for endoscopic cardiac mapping and lead placement
US7398781B1 (en) 1999-08-10 2008-07-15 Maquet Cardiovascular, Llc Method for subxiphoid endoscopic access
US20060287574A1 (en) * 1999-08-25 2006-12-21 Chin Albert K Longitudinal dilator
US6660260B1 (en) * 1999-09-21 2003-12-09 Mayo Foundation For Medical Education And Research Bioprosthetic heart valves
ATE460951T1 (de) 2000-01-25 2010-04-15 Edwards Lifesciences Corp Freisetzungssysteme zur behandlung von restenose und anastomotischer intimaler hyperplasie
US6270779B1 (en) 2000-05-10 2001-08-07 United States Of America Nitric oxide-releasing metallic medical devices
CA2414941C (en) 2000-08-11 2010-12-14 David R. Whitlock Compositions including ammonia oxidizing bacteria to increase production of nitric oxide and nitric oxide precursors and methods of using same
US6797743B2 (en) * 2000-09-27 2004-09-28 Michigan Biotechnology Institute Antimicrobial polymer
US20050043506A1 (en) * 2000-09-27 2005-02-24 Michigan Biotechnology Institute Polyamide materials based on unsaturated carboxylic acids and amines
WO2002030487A2 (en) 2000-10-11 2002-04-18 Micro Thereapeutics, Inc. Methods for treating aneurysms
PT1328213E (pt) 2000-10-16 2005-10-31 Conor Medsystems Inc Dispositivo medico expansivel para a administracao de um agente benefico
US7049308B2 (en) * 2000-10-26 2006-05-23 Duke University C-nitroso compounds and use thereof
US6565601B2 (en) 2000-11-15 2003-05-20 Micro Therapeutics, Inc. Methods for vascular reconstruction of diseased arteries
CA2433861A1 (en) * 2000-12-27 2002-07-04 Genzyme Corporation Controlled release of anti-arrhythmic agents from a biodegradable polyethylene oxide hydrogel for local application to the heart
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
WO2002087508A2 (en) 2001-05-02 2002-11-07 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
WO2003026717A1 (en) * 2001-09-26 2003-04-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nitric oxide-releasing coated medical devices and method of preparing same
US6703046B2 (en) * 2001-10-04 2004-03-09 Medtronic Ave Inc. Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use
JP2005515218A (ja) * 2002-01-11 2005-05-26 ホイットロック,デービッド,アール. アンモニア酸化細菌を含む組成物およびその使用方法
US6939554B2 (en) * 2002-02-05 2005-09-06 Michigan Biotechnology Institute Antimicrobial polymer
WO2003080730A1 (en) 2002-03-20 2003-10-02 Michigan Biotechnology Institute Conductive polymer-based material
US8404665B2 (en) * 2002-03-21 2013-03-26 University Of Utah Research Foundation In vivo use of glutathione S-transferase activated nitric oxide donors
EP1507526A2 (de) * 2002-05-07 2005-02-23 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Polydiazeniumdiolierte cyclische polyamine mit polyphasischer stickoxid-freisetzung und verwandte verbindungen, diese enthaltende zusammensetzungen und anwendungsverfahren dafür
WO2003095623A2 (en) * 2002-05-10 2003-11-20 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating varicella zoster virus and methods of use thereof
JP2005534485A (ja) 2002-08-02 2005-11-17 アメリカ合衆国 架橋した一酸化窒素−放出ポリアミン被覆基質、それを含む組成物及びその製造方法
US6951902B2 (en) * 2002-08-16 2005-10-04 Michigan Biotechnology Institute Two dimensional polymer that generates nitric oxide
EP2289571B1 (de) 2003-03-28 2016-08-03 Innovational Holdings, LLC Implantierbare medizinische vorrichtung mit kontinuerlichem gradienten einer therapeutischen substanz
DK1624953T3 (en) * 2003-04-23 2019-04-01 Univ Akron Sequestered reactive materials
PL1648826T3 (pl) * 2003-07-03 2018-02-28 The University Court Of The University Of St. Andrews Zeolity do dostarczania tlenku azotu
CA2536173A1 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
AU2004270161A1 (en) * 2003-08-28 2005-03-17 Nicox S.A. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7379190B2 (en) * 2004-01-05 2008-05-27 Zygo Corporation Stage alignment in lithography tools
JP2007526911A (ja) * 2004-01-22 2007-09-20 ザ ユニバーシティ オブ アクロン 医療装置および治療のためのポリマーno供与体プレドラッグナノファイバコーティング
WO2005070006A2 (en) * 2004-01-22 2005-08-04 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
US20050165452A1 (en) * 2004-01-28 2005-07-28 Medtronic, Inc. Antithrombogenic medical device
US7829553B2 (en) * 2004-02-09 2010-11-09 Amulet Pharmaceuticals, Inc. Nitric oxide-releasing polymers
US20070191377A1 (en) * 2004-03-31 2007-08-16 Nitromed, Inc. Methods for treating blood disorders with nitric oxide donor compounds
US20060039950A1 (en) * 2004-08-23 2006-02-23 Zhengrong Zhou Multi-functional biocompatible coatings for intravascular devices
EP1794195B1 (de) 2004-09-27 2014-12-17 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Stickoxidabgebende diazeniumdiolisierte acrylnitrilbasierte polymere und zusammensetzungen, medizinische vorrichtungen und verwendungen damit
WO2006041855A2 (en) 2004-10-04 2006-04-20 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
EP1814535A4 (de) * 2004-11-08 2008-06-04 Nitromed Inc Nitrosierte und nitrosylierte verbindungen, zusammensetzungen und verfahren zur behandlung von augenkrankheiten
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
EP1690532A1 (de) * 2005-02-11 2006-08-16 NOLabs AB Vorrichtung zur Behandlung vom Magen und ihr Verfahren zur Herstellung
JP5175107B2 (ja) * 2005-02-11 2013-04-03 ノーラブズ エービー 酸化窒素による神経障害の治療デバイス、方法および使用
WO2006084914A2 (en) * 2005-02-11 2006-08-17 Nolabs Ab Device for gastric treatment and manufacturing process for the same
WO2006093864A1 (en) * 2005-02-28 2006-09-08 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
JP2008533031A (ja) * 2005-03-09 2008-08-21 ニトロメッド インコーポレーティッド アンギオテンシンiiアンタゴニストの有機酸化窒素増強塩、組成物および使用法
JP2008535858A (ja) * 2005-04-07 2008-09-04 ニトロメッド インコーポレーティッド 心不全における遺伝リスク、すなわちnos3の遺伝子変異の影響の評価方法
US20090048219A1 (en) * 2005-05-23 2009-02-19 Nitromed Inc. Organic nitric oxide donor salts of nonsteroidal antiinflammatory compounds, compositions and methods of use
EP2669269B1 (de) 2005-05-27 2019-05-22 The University of North Carolina At Chapel Hill Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen
WO2007005758A2 (en) * 2005-06-30 2007-01-11 Mc3, Inc. Methods , compositions and devices for promoting angiogenesis
CA2613108A1 (en) * 2005-06-30 2007-01-11 Mc3, Inc. Nitric oxide coatings for medical devices
CA2613106A1 (en) * 2005-06-30 2007-01-11 Mc3, Inc. Analyte sensors and compositions for use therein
US20090018091A1 (en) * 2005-08-02 2009-01-15 Nitromed, Inc. Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
US8021679B2 (en) 2005-08-25 2011-09-20 Medtronic Vascular, Inc Nitric oxide-releasing biodegradable polymers useful as medical devices and coatings therefore
US20070053952A1 (en) * 2005-09-07 2007-03-08 Medtronic Vascular, Inc. Nitric oxide-releasing polymers derived from modified polymers
EP1945030A4 (de) * 2005-10-04 2009-10-21 Nitromed Inc Genetische risikobeurteilung bei herzversagen: einfluss der genetischen variation auf den gly389arg-polymorphismus des beta 1 adrenergen rezeptors
AU2006309212B2 (en) * 2005-10-31 2011-09-15 Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Polysaccharide-derived nitric oxide-releasing carbon-bound diazeniumdiolates
WO2007059311A2 (en) * 2005-11-16 2007-05-24 Nitromed, Inc. Furoxan compounds, compositions and methods of use
JP2009518069A (ja) * 2005-12-02 2009-05-07 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン 組成物、コーティング及びデバイス、並びにそれらの製造方法及び使用方法
AU2006322035A1 (en) * 2005-12-06 2007-06-14 Amulet Pharmaceuticals, Inc. Nitric oxide-releasing polymers
EP1968584A2 (de) * 2005-12-20 2008-09-17 Nitromed, Inc. Stickoxid-verstärkende glutaminsäure-verbindungen, zusammensetzungen und anwendungsverfahren
AU2007243765A1 (en) * 2006-03-29 2007-11-08 Nicox S.A. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8241619B2 (en) * 2006-05-15 2012-08-14 Medtronic Vascular, Inc. Hindered amine nitric oxide donating polymers for coating medical devices
US7811600B2 (en) * 2007-03-08 2010-10-12 Medtronic Vascular, Inc. Nitric oxide donating medical devices and methods of making same
US8273828B2 (en) 2007-07-24 2012-09-25 Medtronic Vascular, Inc. Methods for introducing reactive secondary amines pendant to polymers backbones that are useful for diazeniumdiolation
US20100316622A1 (en) * 2007-11-02 2010-12-16 University Of Miami Diagnosis and treatment of cardiac disorders
WO2009064861A2 (en) * 2007-11-13 2009-05-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitric oxide-releasing diazeniumdiolated polymers, compositions, medical devices, and uses thereof
US20090170933A1 (en) * 2007-12-26 2009-07-02 Cook Incorporated Method for removing a medical device from a spasmodic constriction in a bodily passageway
US20090222088A1 (en) * 2008-02-29 2009-09-03 Medtronic Vascular, Inc. Secondary Amine Containing Nitric Oxide Releasing Polymer Composition
WO2009114368A2 (en) 2008-03-07 2009-09-17 University Of Utah Research Foundation Activated nitric oxide donors and methods of making and using thereof
US20090232863A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers
US20090232868A1 (en) * 2008-03-17 2009-09-17 Medtronic Vascular, Inc. Nitric Oxide Releasing Polymer Composition
WO2009123713A1 (en) 2008-04-01 2009-10-08 Cornell University Organo-soluble chitosan salts and chitosan-derived biomaterials prepared thereof
US8158187B2 (en) * 2008-12-19 2012-04-17 Medtronic Vascular, Inc. Dry diazeniumdiolation methods for producing nitric oxide releasing medical devices
US8709465B2 (en) 2009-04-13 2014-04-29 Medtronic Vascular, Inc. Diazeniumdiolated phosphorylcholine polymers for nitric oxide release
US9309347B2 (en) 2009-05-20 2016-04-12 Biomedical, Inc. Bioresorbable thermoset polyester/urethane elastomers
AU2010249558A1 (en) 2009-05-20 2011-12-08 Arsenal Medical, Inc. Medical implant
US8992601B2 (en) 2009-05-20 2015-03-31 480 Biomedical, Inc. Medical implants
US9265633B2 (en) 2009-05-20 2016-02-23 480 Biomedical, Inc. Drug-eluting medical implants
US20110319987A1 (en) 2009-05-20 2011-12-29 Arsenal Medical Medical implant
US8888840B2 (en) * 2009-05-20 2014-11-18 Boston Scientific Scimed, Inc. Drug eluting medical implant
TWI626057B (zh) 2009-06-09 2018-06-11 普龍製藥有限責任公司 血紅素組成物
EP2467127B1 (de) 2009-08-21 2023-08-02 Novan, Inc. Topische gele
WO2011022680A2 (en) 2009-08-21 2011-02-24 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US8372133B2 (en) * 2009-10-05 2013-02-12 480 Biomedical, Inc. Polymeric implant delivery system
US20110301299A1 (en) 2010-06-08 2011-12-08 Medtronic Vascular, Inc. Medical Devices and Polymers Therefor Having PTFE Surfaces Modified With Nitric Oxide-Releasing Polymers
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
ES2695173T3 (es) 2011-02-28 2019-01-02 Novan Inc Partículas de sílice modificadas con S-nitrosotiol que liberan óxido nítrico y procedimientos de fabricación de las mismas
EP2707103A2 (de) 2011-05-09 2014-03-19 Topical Therapeutic Agent (TTA) Ltd. Stickoxidsequestrierung von topischen formulierungen
CN111057660B (zh) 2014-04-15 2023-10-31 Ao生物医学有限责任公司 氨氧化型亚硝化单胞菌菌株d23
US11225640B2 (en) 2014-04-15 2022-01-18 Aobiome Llc Ammonia oxidizing bacteria for treatment of psoriasis
EP3180366B1 (de) * 2014-08-14 2018-09-26 Rohm and Haas Company Polymer mit freisetzbarem gas
DK3253485T3 (da) 2015-02-03 2022-03-21 Univ Court Univ St Andrews No-holdige sammensætninger
WO2018067838A1 (en) 2016-10-07 2018-04-12 The University Of North Carolina At Chapel Hill S-nitrosothiol-mediated hyperbranched polyesters
EP3565848A4 (de) 2017-01-03 2020-09-02 The University of North Carolina at Chapel Hill Stickoxidfreisetzende alginate als biologisch abbaubare antibakterielle gerüste und zugehörige verfahren
CN110461338A (zh) 2017-03-28 2019-11-15 北卡罗来纳大学查佩尔希尔分校 作为可生物降解抗菌支架的释放一氧化氮的聚氨基糖苷类和其制备方法
WO2019173539A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
JP2022516461A (ja) 2018-12-28 2022-02-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 一酸化窒素放出抗菌性ポリマーおよびそれから製造された足場、ならびにそれに関する方法
WO2023081681A1 (en) * 2021-11-03 2023-05-11 Baxter International Inc. Nitric oxide donors for use in surgical recovery

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA998495A (en) * 1971-04-15 1976-10-12 Snamprogetti S.P.A. Modified polyisoprene and process for the preparation thereof
US4954526A (en) * 1989-02-28 1990-09-04 The United States Of America As Represented By The Department Of Health And Human Services Stabilized nitric oxide - primary amine complexes useful as cardiovascular agents
US5208233A (en) * 1989-09-15 1993-05-04 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5039705A (en) * 1989-09-15 1991-08-13 The United States Of America As Represented By The Department Of Health And Human Services Anti-hypertensive compositions of secondary amine-nitric oxide adducts and use thereof
US5212204A (en) * 1989-10-18 1993-05-18 The United States Of America As Represented By The Department Of Health And Human Services Antihypertensive compositions and use thereof
US5155137A (en) * 1990-09-20 1992-10-13 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Complexes of nitric oxide with polyamines
US5185376A (en) * 1991-09-24 1993-02-09 The United States Of America As Represented By The Department Of Health And Human Services Therapeutic inhibition of platelet aggregation by nucleophile-nitric oxide complexes and derivatives thereof
US5219710A (en) * 1991-11-25 1993-06-15 Allied-Signal Inc. Polymeric nitrones having a styrene-derived backbone chain

Also Published As

Publication number Publication date
AU698525B2 (en) 1998-10-29
DE69526934T2 (de) 2003-01-02
US5650447A (en) 1997-07-22
EP0752866B1 (de) 2002-06-05
WO1995024908A1 (en) 1995-09-21
PT752866E (pt) 2002-11-29
CA2185457A1 (en) 1995-09-21
ES2177637T3 (es) 2002-12-16
JPH10502905A (ja) 1998-03-17
ATE218352T1 (de) 2002-06-15
DK0752866T3 (da) 2002-09-16
EP0752866A1 (de) 1997-01-15
AU1988995A (en) 1995-10-03
CA2185457C (en) 2004-05-25

Similar Documents

Publication Publication Date Title
DE69526934D1 (de) Medikamente zur behandlung von restenosis, enthaltend stickstoff freisetzende polymere
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
BR9814389A (pt) Forma de dosagem farmacêutica revestida entérica, processo para a preparação da mesma, uso desta, pelota ou tablete encamado para a mesma, e, processos para melhorar a inibição da secreção de ácido gástrico, e para melhorar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com secreção de ácido em excesso
DE69230046D1 (de) 2-Bromomelatonin zur Behandlung von Schlafstörungen
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
ATE311867T1 (de) Analgetische zusammensetzung enthaltend antiepileptische arzneistoffe und deren verwendungen
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
DE69805202T2 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
DE69906671D1 (de) Substituierte 2-Phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanone, deren Verwendung zur Behandlung von Erkrankungen des zentralen und periphären Nervensystems und diese enthaltende pharmazeutische Zusammensetzungen
ATE171869T1 (de) Film zur lokalen arzneistoffabgabe für periodontale behandlung
DE69826023D1 (de) Verwendung von substanzen mit oxytocinwirkung zur herstellung eines arzneimittels zur behandlung affektiver schmerzsyndrome
DE69424777T2 (de) 3,4-diarylchromane zur behandlung von dermatitis
BR9500436A (pt) Produtos uso de um g-csf uso de uma proteína tnf ligante processo para o tratamento e/ou prevenção do choque séptico
CA2156481A1 (en) 5-ht2 receptor antagonist compositions useful in treating venous conditions
ATE232390T1 (de) Osmotisches nicht-fermentiertes laxans zur behandlung und vorbeugung von kolorektalem krebs
ATE275966T1 (de) Activin stimulator enthaltende pharmazeutische zusammensetzung
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
ATE255411T1 (de) Hyaluronsäurerezeptoren bindende stoffe und deren verwendung zur behandlung von tumoren und restenose
NZ594154A (en) Transdermal administration of buprenorphine for preoperative treatment of post operative pain
DE69623316T2 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ATE247965T1 (de) Paracetamol und buspiron enthaltende pharmazeutische zusammensetzung mit analgetischer wirkung
BR9808063A (pt) Métodos para tratamento de distúrbios vasculares.
HUP9801628A2 (hu) Artritisz elleni gyógyászati készítmények
DE60006284D1 (de) Arzneimittel zur behandlung konvulsivischer zustände
DE69729120D1 (de) Arzneipräparat und verfahren zur behandlung und vorbeugung von fybromyalgie und des chronischen ermüdungssyndrom

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee